Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Recruiting · NCT06296745 · Registry updated 2026-01-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, lung disorder, lung neoplasm, neoplasm, neoplastic meningitis, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, tumor of meninges | Recruiting | Phase 2 | 2026-01-30 | NCT06296745 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Medical University | 33 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Affiliated Huizhou Hospital, Guangzhou Medical University | Huizhou | China | 6 |